Click to search for your profile
Click to search for condition or expert
Click to open main menu
Save Condition
Bookmark
Share
Share
Condition
Progressive Supranuclear Palsy Atypical
Symptoms, Doctors, Treatments, Advances & More
Overview
Find a Doctor
Latest Advances
Clinical Trials
Condition 101
About Progressive Supranuclear Palsy Atypical
What are the alternative names for Progressive Supranuclear Palsy Atypical?
Atypical PSP
Top Global Doctors
For Progressive Supranuclear Palsy Atypical
Bookmark
Click to see options
GH
Elite
Gunter U. Hoglinger
Hannover, NI, DE
Bookmark
Click to see options
MG
Elite
Murray C. Grossman
Neurology
Urology
Psychiatry
Philadelphia, PA
Bookmark
Click to see options
AB
Elite
Adam L. Boxer
Neurology
Urology
Addiction Medicine
San Francisco, CA
Bookmark
Click to see options
IL
Elite
Irene Litvan
Neurology
Urology
Addiction Medicine
La Jolla, CA
Bookmark
Click to see options
LG
Elite
Lawrence I. Golbe
Neurology
Urology
Addiction Medicine
New Brunswick, NJ
Bookmark
Click to see options
JL
Elite
Johannes Levin
Munich, BY, DE
Latest Advances
On Progressive Supranuclear Palsy Atypical
Condition:
Long-term Neurological Conditions
Journal:
JAMA network open
Treatment Used:
Short-term Integrated Palliative Care
Number of Patients:
350
Published —
August 29, 2020
In this study, researchers evaluated the outcomes of short-term integrated palliative care for patients with long-term neurological conditions.
Condition:
Niemann-Pick disease Type C (NP-C)
Journal:
Orphanet journal of rare diseases
Treatment Used:
Continuous Miglustat Therapy
Number of Patients:
472
Published —
April 27, 2020
This study reported data on the treatment of patients with Niemann-Pick disease Type C (NP-C), a rare, progressive neurodegenerative disorder.
Clinical Trials
For Progressive Supranuclear Palsy Atypical
Clinical Trial
Status:
Not yet recruiting
Intervention Type:
Other
Participants:
165
Start Date:
March 2021
MotOr, cogniTIVe and Imaging charactErization of Progressive Supranuclear Palsy Phenotypes: a Longitudinal Prospective Study Looking for Biomarkers
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
15
Start Date:
January 22, 2021
A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients With the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome.